• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Synergy Pharmaceuticals appoints Gary G. Gemignani chief financial officer

Synergy Pharmaceuticals appoints Gary G. Gemignani chief financial officer

April 18, 2017
CenterWatch Staff

Synergy Pharmaceuticals announced that Gary G. Gemignani has been appointed as executive vice president and chief financial officer, effective April 17, 2017. Gemignani replaces senior vice president, Finance, Bernard Denoyer, who will assist in the transition process until his retirement on July 1, 2017.

Gemignani’s career in healthcare spans over three decades, including senior management positions at several pharmaceutical and biopharmaceutical companies. Most recently, he served as chief executive officer and chief financial officer of Biodel (now Albireo), overseeing business and strategic planning, operations and financing activities of the company. During his tenure, Gemignani successfully led the reverse merger with Albireo and managed several corporate restructurings to strengthen Albireo’s overall financial position. Prior to this role, Mr. Gemignani served in senior and executive financial and operational roles with multiple public and private companies including Coronado Biosciences, Gentium, Novartis Pharmaceutical and Wyeth.

“We are very fortunate to have Gary Gemignani stepping into the critical leadership role of CFO as Synergy moves into our next chapter as a commercial company,” said Gary S. Jacob, Ph.D., chairman and chief executive officer of Synergy Pharmaceuticals. “Gary brings extensive expertise in financial and operational management, business development and strategic planning to Synergy, and a proven track record of driving significant shareholder value. We look forward to Gary’s contributions as we continue to optimize the TRULANCE launch and efficiently capitalize on this opportunity.”

“I am thrilled to join Synergy at such a transformative time in the company’s history,” said Gary Gemignani. “I look forward to working with Gary and his team of talented, dedicated employees to maximize the value of its core, high value asset, TRULANCE, and leverage the solid foundation it now has in place to drive further growth. This is a unique opportunity to be a part of a company that is passionate, highly energized and committed to accomplishing the extraordinary and making a real difference in the lives of patients.”

Gary Gemignani’s appointment as EVP and CFO comes with the announcement of the impending retirement of Bernard Denoyer, senior vice president, Finance of Synergy Pharmaceuticals. Denoyer has been with Synergy from its outset as a public company in July, 2008, and has made lasting contributions to the company.

“Bernard has been an outstanding contributor to our success,” added Dr. Jacob. “He helped build the strong financial foundation that has supported our ongoing evolution from a successful research and development company to a fully integrated commercial organization. We appreciate his dedication to Synergy and are pleased he will continue to serve the company during this time of transition.”

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing